Advertisement

Association Between Hypertension, Platelet Reactivity, and the Risk of Adverse Events After Percutaneous Coronary Intervention (From the ADAPT-DES Study)

      Hypertension is associated with vascular and endothelial dysfunction that may result in a greater propensity for reactive platelets to cause thrombosis. We sought to assess whether the risk of major adverse cardiac events (MACE) after percutaneous coronary intervention (PCI) in patients with on-clopidogrel residual high platelet reactivity (HPR) varies in patients with versus without hypertension. Assessment of dual antiplatelet therapy with drug eluting stents (ADAPT-DES) was a prospective, multicenter registry of patients successfully treated with coronary drug-eluting stents (DES). HPR was defined as P2Y12 reaction units (PRU) >208, as assessed by the VerifyNow point-of-care assay. Multivariable Cox proportional hazards regression was used to assess whether the adjusted association between HPR and 2-year risk of MACE (cardiac death, myocardial infarction [MI], or stent thrombosis) was different in patients with versus without hypertension. A total of 6833 of 8582 patients (79.6%) had a history of hypertension. Patients with compared with those without hypertension were older, more likely to have other cardiovascular risk factors, and had higher PRU (190.1 ± 97.3 vs 179.5 ± 94.3; p <0.0001). Patients with hypertension had significantly higher 2-year rates of MACE (7.0% vs 4.4%, p <0.001), all-cause death (4.2% vs 2.5%, p = 0.001), and MI (5.2% vs 3.2%, p <0.001), and had nominally higher rates of stent thrombosis (1.0% vs 0.5%, p = 0.059). A significant interaction was present between hypertension and HPR regarding 2-year MACE risk (adjusted hazard ratio for HPR vs no HPR 1.38, 95% confidence interval 1.14 to 1.68 for patients with hypertension vs 0.81, 95% confidence interval 0.50 to 1.33 for patients without hypertension, p = 0.046). In conclusion, following successful PCI with DES, 2-year MACE rates are increased in patients with both hypertension and residual HPR on clopidogrel. HPR had a greater effect on the risk of adverse events among patients with versus without hypertension.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Brar SS
        • ten Berg J
        • Marcucci R
        • Price MJ
        • Valgimigli M
        • Kim HS
        • Patti G
        • Breet NJ
        • DiSciascio G
        • Cuisset T
        • Dangas G
        Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data.
        J Am Coll Cardiol. 2011; 58: 1945-1954
        • Stone GW
        • Witzenbichler B
        • Weisz G
        • Rinaldi MJ
        • Neumann FJ
        • Metzger DC
        • Henry TD
        • Cox DA
        • Duffy PL
        • Mazzaferri E
        • Gurbel PA
        • Xu K
        • Parise H
        • Kirtane AJ
        • Brodie BR
        • Mehran R
        • Stuckey TD
        • ADAPT-DES Investigators
        Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study.
        Lancet. 2013; 382: 614-623
        • Falk E
        • Nakano M
        • Bentzon JF
        • Finn AV
        • Virmani R
        Update on acute coronary syndromes: the pathologists' view.
        Eur Heart J. 2013; 34: 719-728
        • Landmesser U
        • Hornig B
        • Drexler H
        Endothelial function: a critical determinant in atherosclerosis.
        Circulation. 2004; 109 (II27-33)
        • Widlansky ME
        • Gokce N
        • Keaney Jr., JF
        • Vita JA
        The clinical implications of endothelial dysfunction.
        J Am Coll Cardiol. 2003; 42: 1149-1160
        • Panza JA
        • Quyyumi AA
        • Brush Jr., JE
        • Epstein SE
        Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension.
        N Engl J Med. 1990; 323: 22-27
        • Blann AD
        • Naqvi T
        • Waite M
        • McCollum CN
        von Willebrand factor and endothelial damage in essential hypertension.
        J Hum Hypertens. 1993; 7: 107-111
        • Boulanger CM
        Secondary endothelial dysfunction: hypertension and heart failure.
        J Mol Cell Cardiol. 1999; 31: 39-49
        • Poli KA
        • Tofler GH
        • Larson MG
        • Evans JC
        • Sutherland PA
        • Lipinska I
        • Mittleman MA
        • Muller JE
        • D'Agostino RB
        • Wilson PW
        • Levy D
        Association of blood pressure with fibrinolytic potential in the Framingham offspring population.
        Circulation. 2000; 101: 264-269
        • Witzenbichler B
        • Maehara A
        • Weisz G
        • Neumann FJ
        • Rinaldi MJ
        • Metzger DC
        • Henry TD
        • Cox DA
        • Duffy PL
        • Brodie BR
        • Stuckey TD
        • Mazzaferri Jr., EL
        • Xu K
        • Parise H
        • Mehran R
        • Mintz GS
        • Stone GW
        Relationship between intravascular ultrasound guidance and clinical outcomes after drug-eluting stents: the assessment of dual antiplatelet therapy with drug-eluting stents (ADAPT-DES) study.
        Circulation. 2014; 129: 463-470
        • Reny JL
        • Fontana P
        • Hochholzer W
        • Neumann FJ
        • Ten Berg J
        • Janssen PW
        • Geisler T
        • Gawaz M
        • Marcucci R
        • Gori AM
        • Cuisset T
        • Alessi MC
        • Berdague P
        • Gurbel PA
        • Yong G
        • Angiolillo DJ
        • Aradi D
        • Beigel R
        • Campo G
        • Combescure C
        Vascular risk levels affect the predictive value of platelet reactivity for the occurrence of MACE in patients on clopidogrel. Systematic review and meta-analysis of individual patient data.
        Thromb Haemost. 2016; 115: 844-855
        • Kukreja N
        • Onuma Y
        • Garcia-Garcia HM
        • Daemen J
        • van Domburg R
        • Serruys PW
        • Interventional Cardiologists of the Thoraxcenter
        The risk of stent thrombosis in patients with acute coronary syndromes treated with bare-metal and drug-eluting stents.
        JACC Cardiovasc Interv. 2009; 2: 534-541
        • Planer D
        • Smits PC
        • Kereiakes DJ
        • Kedhi E
        • Fahy M
        • Xu K
        • Serruys PW
        • Stone GW
        Comparison of everolimus- and paclitaxel-eluting stents in patients with acute and stable coronary syndromes: pooled results from the SPIRIT (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (A Trial of Everolimus-Eluting Stents and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice) trials.
        JACC Cardiovasc Interv. 2011; 4: 1104-1115
        • Palmerini T
        • Della Riva D
        • Benedetto U
        • Bacchi Reggiani L
        • Feres F
        • Abizaid A
        • Gilard M
        • Morice MC
        • Valgimigli M
        • Hong MK
        • Kim BK
        • Jang Y
        • Kim HS
        • Park KW
        • Colombo A
        • Chieffo A
        • Sangiorgi D
        • Biondi-Zoccai G
        • Genereux P
        • Angelini GD
        • Pufulete M
        • White J
        • Bhatt DL
        • Stone GW
        Three, six, or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes: an individual patient data pairwise and network meta-analysis of six randomized trials and 11 473 patients.
        Eur Heart J. 2017; 38: 1034-1043
        • Saluveer O
        • Redfors B
        • Angeras O
        • Dworeck C
        • Haraldsson I
        • Ljungman C
        • Petursson P
        • Odenstedt J
        • Ioanes D
        • Lundgren P
        • Volz S
        • Ramunddal T
        • Andersson B
        • Omerovic E
        • Bergh N
        Hypertension is associated with increased mortality in patients with ischaemic heart disease after revascularization with percutaneous coronary intervention - a report from SCAAR.
        Blood Press. 2017; 26: 166-173
        • Wallentin L
        • Becker RC
        • Budaj A
        • Cannon CP
        • Emanuelsson H
        • Held C
        • Horrow J
        • Husted S
        • James S
        • Katus H
        • Mahaffey KW
        • Scirica BM
        • Skene A
        • Steg PG
        • Storey RF
        • Harrington RA
        • PLATO Investigators
        Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
        N Engl J Med. 2009; 361: 1045-1057
        • Wiviott SD
        • Braunwald E
        • McCabe CH
        • Montalescot G
        • Ruzyllo W
        • Gottlieb S
        • Neumann FJ
        • Ardissino D
        • De Servi S
        • Murphy SA
        • Riesmeyer J
        • Weerakkody G
        • Gibson CM
        • Antman EM
        • TRITON-TIMI IInvestigators
        Prasugrel versus clopidogrel in patients with acute coronary syndromes.
        N Engl J Med. 2007; 357: 2001-2015
        • Shahin Y
        • Khan JA
        • Samuel N
        • Chetter I
        Angiotensin converting enzyme inhibitors effect on endothelial dysfunction: a meta-analysis of randomised controlled trials.
        Atherosclerosis. 2011; 216: 7-16
        • Dandona P
        • Dhindsa S
        • Ghanim H
        • Chaudhuri A
        Angiotensin II and inflammation: the effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade.
        J Hum Hypertens. 2007; 21: 20-27
        • Cameron AC
        • Lang NN
        • Touyz RM
        Drug treatment of hypertension: focus on vascular health.
        Drugs. 2016; 76: 1529-1550
        • Blann AD
        • Nadar S
        • Lip GY
        Pharmacological modulation of platelet function in hypertension.
        Hypertension. 2003; 42: 1-7
        • Siller-Matula JM
        • Lang I
        • Christ G
        • Jilma B
        Calcium-channel blockers reduce the antiplatelet effect of clopidogrel.
        J Am Coll Cardiol. 2008; 52: 1557-1563
        • Ojeifo O
        • Wiviott SD
        • Antman EM
        • Murphy SA
        • Udell JA
        • Bates ER
        • Mega JL
        • Sabatine MS
        • O'Donoghue ML
        Concomitant administration of clopidogrel with statins or calcium-channel blockers: insights from the TRITON-TIMI 38 (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38).
        JACC Cardiovasc Interv. 2013; 6: 1275-1281
        • Good CW
        • Steinhubl SR
        • Brennan DM
        • Lincoff AM
        • Topol EJ
        • Berger PB
        Is there a clinically significant interaction between calcium channel antagonists and clopidogrel?: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial.
        Circ Cardiovasc Interv. 2012; 5: 77-81